Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 4/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.31 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834509 | 1.00 | KRAS (0.41) | KRASGRM7ATRCYP4F2CYP4A11 | |
| SCHEMBL30834532 | 0.88 | KRAS (0.37) | KRASGRM7ATRCYP4F2CYP4A11 | |
| SCHEMBL21733779 | 0.88 | KRAS (0.37) | KRASGRM7ATRCYP4F2CYP4A11 | |
| SCHEMBL21733673 | 0.87 | KRAS (0.52) | KRASGRM7RXRARXRBRXRG | |
| SCHEMBL30834490 | 0.87 | KRAS (0.52) | KRASGRM7RXRARXRBRXRG | |
| SCHEMBL21722208 | 0.87 | KRAS (0.48) | KRASATRCYP4F2CYP4A11RXRA | |
| SCHEMBL21243885 | 0.86 | KRAS (0.41) | KRASATR | |
| SCHEMBL21243918 | 0.81 | GRM7 (0.41) | KRASGRM7ATRCYP4F2CYP4A11 | |
| SCHEMBL24854457 | 0.81 | KRAS (0.41) | KRASGRM7DRD2HTR2CCYP1A2 | |
| SCHEMBL21243935 | 0.77 | KRAS (0.61) | KRASGRM7HTR2CCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885GRM7 2937/4885ATR 1578/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885GRM7 2937/4885ATR 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.